NMT Arbitration Ends With Sale Of Disputed Vena Cava Assets To Bard
This article was originally published in The Gray Sheet
Executive Summary
Expanded commercialization of NMT Medical's CardioSeal cardiac septal occluder system will be funded in part by the recent sale of the firm's vena cava filter business to C.R. Bard for up to $34 mil. plus royalties.